The NCPE believe that, at the submitted price, Abiraterone Acetate (Zytiga®) is not cost effective for the treatment of metastatic castration resistant prostate cancer in patients who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated
Eltrombopag (Revolade®) is indicated in adult patients with chronic hepatitis C virus (HCV) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy Rapid Review Commenced Completed Outcome 10/01/2014 13/02/2014 Full Pharmacoeconomic Evaluation not Recommended.
The NCPE believe that when compared to alternative biological agents aflibercept may be considered cost saving.
The NCPE does not recommend reimbursement of vismodegib.
The NCPE do not recommend reimbursement of dapagliflozin.
The NCPE do not recommend reimbursement of Subcutaneous Abatacept (Orencia®) at the submitted price.
Pregabalin is currently reimbursed. The NCPE consider that it may be cost effective under certain assumptions.
The NCPE believes that pertuzumab in combination with trastuzumab and docetaxel is not a cost-effective treatment for adults with HER2-positive metastatic or locally recurrent unresectable breast cancer who have not received previous anti-HER2 therapy or chemotherapy.
The NCPE do not consider Crizotinib (Xalkori) a cost-effective treatment for adult patients with previously treated ALK positive advanced non small cell lung cancer (NSCLC).
The NCPE do not consider ruxolitinib to be a cost effective treatment of splenomegaly or disease-related symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.